FDA approves T-DM1 for metastatic breast cancer

The USA Food and Drug Administration (FDA) approved on 22 February 2013 antibody-drug conjugate, Kadcyla (ado-trastuzumab emtansine or T-DM1), a new therapy for patients with HER2-positive, metastatic breast cancer. Kadcyla is intended for patients who were previously treated with trastuzumab, another anti-HER2 therapy, and taxanes. Read more here.